Nine developments over the past ten months that change the picture for anyone running or siting clinical research in the Caribbean. Every item is sourced and dated. Our read on why each one matters is our own.
The Caribbean is usually written about in clinical research circles in the future conditional — what the region could offer, what it might become. The past ten months have been unusually concrete. A precision medicine institute announced its first Barbados research project. Grenada broke ground on a 250-bed teaching hospital with a US academic partner. PAHO and CARPHA signed a five-year framework that names the regional medicines pathway as a priority through 2030.
Here is what happened, in order of how much it matters to anyone actually trying to run a study here.
1. BioMed X announces its first Barbados research project, on early diabetic kidney disease
27 January 2026
BioMed X announced its first Barbados research project, with the Government of Barbados and the EU's PharmaNext Programme, and opened a call for applications to build the research team. The planned study will perform deep molecular profiling of Barbadian type 2 diabetes patients with early kidney disease against matched healthy controls, combining biosamples with AI modelling to build a population-specific model for patient stratification and biomarker discovery. The stated rationale is the under-representation of people of African descent in precision medicine. Note the stage: this is a project launch and a team recruitment call, not patient recruitment.
Why it matters. This is the clearest example in the region of a planned Caribbean-recruited, biosample-driven translational study designed to produce stratification biomarkers. It is exactly the upstream work that generates downstream trial demand — and it establishes that a European institute judged Barbados capable of delivering it.
2. Grenada breaks ground on Project Polaris with Mount Sinai
Late March 2026; Mount Sinai announcement 2 April 2026
The Government of Grenada held the sod-turning for Project Polaris at Calivigny, St George — a 250-bed climate-smart teaching hospital on an 84-acre medical city site, targeted for completion in 2029 and replacing the existing General Hospital. Mount Sinai International has worked on the clinical model, care delivery design, workforce strategy and operational plans. The facility is explicitly intended to support medical education and research alongside clinical services.
Why it matters. A purpose-built teaching hospital with a US academic medical centre as partner is the single largest potential addition to Eastern Caribbean trial-site infrastructure this decade. Note the timeline honestly: 2029 is a long way from a first-patient-in.
Mount Sinai Health System · Caribbean News Global
3. PAHO and CARPHA sign a 2026–2030 framework naming the Caribbean Regulatory System
13 February 2026
PAHO and CARPHA signed a five-year framework agreement under the PAHO-CARICOM Joint Subregional Cooperation Strategy. The named technical areas include the Caribbean Regulatory System, laboratory strengthening, non-communicable diseases, climate resilience and environmental health, foodborne disease preparedness and risk communication. Both agencies framed it as reducing duplication for member states.
Why it matters. Naming the Caribbean Regulatory System as a joint priority through 2030 signals continued institutional backing for the regional medicines assessment and vigilance pathway. One caveat worth stating plainly, because it is widely misunderstood: the CRS handles marketing authorisation recommendations and pharmacovigilance. It does not authorise clinical trials. That remains a national function in every member state.
4. The same partnership sets an NCD surveillance work programme
13 April 2026
Meeting in Bridgetown, PAHO and CARPHA agreed a technical work programme under their shared framework. Priorities include harmonising NCD surveillance indicators and data-sharing mechanisms, developing regional analytical tools, strengthening cancer registry data quality, violence and injury surveillance, and diabetes and nutrition clinical pathways. The work aligns to PAHO's Strategic Plan 2026–2031.
Why it matters. This is less visible than a new hospital and arguably more useful. Harmonised NCD indicators and better cancer registries directly improve the feasibility data and epidemiological denominators a sponsor needs to justify siting a study in CARICOM. Right now, comparing prevalence between two Caribbean countries often means reconciling three different definitions and four different reference years.
5. CARPHA's 70th conference draws 196 accepted papers to Guyana
22–24 April 2026
CARPHA and Guyana's Ministry of Health hosted the 70th Annual Health Research Conference at the Arthur Chung Conference Centre, themed Innovations in Health. Around 500 delegates from more than twenty countries attended; 211 papers were submitted and 196 accepted, with twelve feature speakers, including researchers from Oxford, Harvard, Imperial, McMaster and the UK Health Security Agency. Four concurrent session tracks were dedicated to non-communicable disease. Abstracts are published in the West Indian Medical Journal.
Why it matters. Abstract volume is a reasonable proxy for regional investigator capacity, and this is the best annual shop window for identifying Caribbean principal investigators and site partners. We attended — our fuller notes are here.
Jamaica Observer · Kaieteur News
6. Mount Sinai and Guyana launch a hospital quality and patient safety programme
27 March 2026
Mount Sinai Health System and Guyana's Ministry of Health launched a quality improvement programme across six newly built regional hospitals — Lima Sands, De Kinderen, Diamond, Enmore, Bath Settlement and No. 75 Village. It focuses on emergency department triage protocols, patient identification systems and medication safety, with ongoing Mount Sinai technical assistance. It sits within Guyana's National Healthcare Initiative, running to 2030.
Why it matters. Patient identification and medication safety systems are not adjacent to GCP — they are prerequisites for it. This materially raises the trial-readiness ceiling of Guyana's new hospital estate, in a country that has the largest South Asian-descent population share in the Americas and correspondingly distinct cardiometabolic phenotypes.
7. Regional stocktake: only three states on track for 2025 NCD targets
5 June 2026
The Healthy Caribbean Coalition, PAHO, CARPHA and the OECS Commission convened a stocktake on healthy food policy. Presenters reported that among Americas member states, only Antigua and Barbuda, Barbados and Grenada were on track to meet 2025 NCD targets. The session drew on a regional survey of roughly 67,000 children and noted that over 75% of Jamaica's adult population consumes at least one sweetened beverage daily. Dr Heather Armstrong observed that policy implementation and enforcement remain slow and uneven.
Why it matters. Uncomfortable to read and important to state. The scale of unmet NCD targets is the quantified version of the region's chronic disease burden — which is, bluntly, the core commercial argument for siting cardiometabolic trials in the Caribbean. Prevention policy failing and trial opportunity growing are the same fact viewed from two directions.
8. CARPHA opens a WHO Type C Regional Emergency Operations Centre
3 July 2026
CARPHA inaugurated a Regional Emergency Operations Centre at its Port of Spain headquarters, classified WHO Type C — the highest level — serving its 26 member states. It is EU-funded under the 11th EDF health security programme and runs on the Regional Integrated Early Warning Surveillance and Response System, providing regional risk assessments, situational awareness and coordinated outbreak response.
Why it matters. A functioning regional surveillance and response backbone is what makes rapid outbreak-response trial activation credible in the Caribbean rather than aspirational. It is infrastructure that only proves its value when something goes wrong.
Discover Montserrat · TTT News
9. UKHSA, PAHO and CARPHA run a diabetes and NCD workshop for six UK Overseas Territories
3–7 November 2025
A regional workshop in Bridgetown convened Anguilla, Bermuda, the British Virgin Islands, the Cayman Islands, Montserrat and the Turks and Caicos Islands, plus St Helena as guest. It covered clinical pathways, patient care fundamentals, surveillance improvement, laboratory capacities and workforce skills development, with each territory developing an action plan. Funded by the UK Foreign, Commonwealth and Development Office through the Civil Resilience Fund.
Why it matters. Standardised diabetes clinical pathways across the UK Overseas Territories improve the consistency of standard-of-care comparator arms and the quality of routine data for any NCD study spanning them. For a UK-linked network, the FCDO funding route is also worth noting.
Also worth knowing
UWI Cave Hill has expanded mandatory ethics training in its medical curriculum, adding two credits at Year Four with reinforcement in Year Five and making ethics conferences mandatory for undergraduate and postgraduate students. Dean Dr Damian Cohall described the change as already in place when he set it out on 18 July 2026. A larger pool of formally ethics-trained clinicians is the feedstock for future investigators and research ethics committee members across Barbados and the Eastern Caribbean. (Barbados Today)
PAHO reported in April 2026 on the Caribbean AMR Catch-up, an established monthly community of practice under the UK Fleming Fund-supported AMR programme, linking stewardship to laboratory capacity-building and surveillance. AMR laboratory strengthening builds the microbiology capability anti-infective trials require from sites. (PAHO)
The pattern
Read together, these nine items describe a region whose research support infrastructure is improving considerably faster than its clinical trial infrastructure. Surveillance, pharmacovigilance, emergency response, hospital quality systems, ethics training and regulatory cooperation have all moved forward in the past ten months. Interventional research capacity has moved much less.
That is not a criticism. It is the correct order to build in — you cannot run credible trials on top of weak safety reporting and inconsistent patient identification. But it does mean the foundations are now further ahead than the thing they were laid for, and the gap is a commercial opportunity for anyone prepared to do the operational work of closing it.
We publish these round-ups periodically. If we have missed something, tell us — we would rather be corrected than incomplete.